News Merus N.V.

Equities

MRUS

NL0011606264

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
44.93 ^USD	+7.05%		+11.02%	+63.38%

Apr. 19	Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	MT
Mar. 28	Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting	Apr. 24	GL
Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	Apr. 19	MT
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024	Apr. 08	GL
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024	Apr. 08	AQ
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 03	GL
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 03	AQ
Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target	Mar. 28	MT
Needham Raises Price Target on Merus to $66 From $65, Maintains Buy Rating	Mar. 07	MT
Gilead Sciences, Merus Collaborate to Discover New Potential Cancer Therapies	Mar. 06	MT
Gilead, Merus to Collaborate on Trispecific Antibody Research	Mar. 06	DJ
Gilead Sciences, Inc. and Merus N.V. Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers	Mar. 06	CI
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression	Mar. 05	GL
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression	Mar. 05	AQ
Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc.	Mar. 04	CI
Needham Raises Price Target on Merus to $65 From $42, Keeps Buy Rating	Mar. 04	MT
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference	Mar. 04	GL
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference	Mar. 04	AQ
Merus Full-Year 2023 Net Loss Widens, Revenue Increases	Feb. 28	MT
Earnings Flash (MRUS) MERUS N.V. Posts 2023 Revenue $43.95M	Feb. 28	MT
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update	Feb. 28	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Merus N.V.

Equities

MRUS

NL0011606264

Summary

Filters